PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study

The foundational phase II report investigated whether the PRaG triplet could produce responses in previously treated metastatic cancer.

Frontiers in immunology · Jul 8, 2022
Original authors: Yuehong Kong, Xiangrong Zhao, Meiling Xu, Jie Pan, Yifu Ma, Li Zou, Qiliang Peng, Junjun Zhang, Cunjin Su, Zhi Xu, Wei Zhou, Yong Peng, Jiabao Yang, Chengliang Zhou, Yujia Li, Qiuchen Guo, Guangqiang Chen, Hongya Wu, Pengfei Xing, Liyuan Zhang

Read the results alongside the study design, safety findings and limitations.

Who was studied?

54 patients with metastatic solid tumors refractory to standard systemic treatment.

54Enrolled

16.7%ORR · ITT

4.0 monthsMedian PFS

10.5 monthsMedian OS

What does the publication report?

In the intention-to-treat population, ORR was 16.7% and DCR 46.3%. Median PFS was 4.0 months and median OS 10.5 months.

Safety findings

Five grade 3 and one grade 4 treatment-related adverse events were reported (10.0% and 2.0% in the reported safety population).

How should we interpret it?

Single-arm design, heterogeneous cancers and a small sample prevent a causal comparison with standard care.

Read the original source

This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.

PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study · DOI: 10.3389/fimmu.2022.952066 · PMID: 35874780

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.